<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2026-076</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-10254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНТЕРСТИЦИАЛЬНЫЕ БОЛЕЗНИ ЛЕГКИХ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERSTITIAL LUNG DISEASE</subject></subj-group></article-categories><title-group><article-title>Особенности клинических и функциональных параметров у пациентов с интерстициальными поражениями легких различной этиологии в сочетании с сахарным диабетом</article-title><trans-title-group xml:lang="en"><trans-title>Features of clinical and functional parameters in patients with interstitial lung diseases of various origin and diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6917-3220</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аличубанова</surname><given-names>Г. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Alichubanova</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аличубанова Гюлжаган Эльдаровна - аспирант, Центральный научно-исследовательский институт туберкулеза; младший научный сотрудник отделения пульмонологии, Московский областной НИКИ имени М.Ф. Владимирского.</p><p>107564, Москва, Яузская аллея, д. 2; 129110, Москва, ул. Щепкина, д. 61/2</p></bio><bio xml:lang="en"><p>Gulzhagan Е. Alichubanova - Postgraduate Student, Central Scientific Research Institute of Tuberculosis; Junior Researcher of the Department of Pulmonology, Moscow Regional Research and Clinical Institute (“MONIKI”);</p><p>2, Yauzskaya Alley, Moscow, 107564; 61/2, Schepkin St., Moscow, 129110</p></bio><email xlink:type="simple">alichubanova98@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6390-8759</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарьянц</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Makaryants</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макарьянц Наталья Николаевна - д.м.н., профессор, главный внештатный специалист-пульмонолог Министерства здравоохранения Московской области, заведующая курсом пульмонологии кафедры терапии, руководитель отделения пульмонологии, Московский областной НИКИ имени М.Ф. Владимирского.</p><p>129110, Москва, ул. Щепкина, д. 61/2; SPIN-код: 6455-6060</p></bio><bio xml:lang="en"><p>Natalia N. Makaryants - Dr. Sci. (Med.), Professor, Chief Freelance Specialist-Pulmonologist of the Ministry of Health of the Moscow Region, Head of the Pulmonology course of the Department of Therapy, Head of the Department of Pulmonology, “MONIKI”.</p><p>61/2, Schepkin St., Moscow, 129110</p></bio><email xlink:type="simple">makaryantz@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крахоткина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krakhotkina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крахоткина Анастасия Андреевна - научный сотрудник отделения пульмонологии, ассистент курса пульмонологии кафедры терапии, врач-пульмонолог.</p><p>129110, Москва, ул. Щепкина, д. 61/2</p></bio><bio xml:lang="en"><p>Anastasia А. Krakhotkina, Researcher of the Department of Pulmonology, Assistant Professor of Pulmonology course of the Department of Therapy, Pulmonologist, “MONIKI”.</p><p>61/2, Schepkin St., Moscow, 129110</p></bio><email xlink:type="simple">sycheva.nst@ya.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Центральный научно-исследовательский институт туберкулеза; Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Scientific Research Institute of Tuberculosis; Moscow Regional Research and Clinical Institute (“MONIKI”)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute (“MONIKI”)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>14</day><month>07</month><year>2026</year></pub-date><volume>0</volume><issue>9</issue><fpage>106</fpage><lpage>112</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аличубанова Г.Э., Макарьянц Н.Н., Крахоткина А.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Аличубанова Г.Э., Макарьянц Н.Н., Крахоткина А.А.</copyright-holder><copyright-holder xml:lang="en">Alichubanova G.A., Makaryants N.N., Krakhotkina A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/10254">https://www.med-sovet.pro/jour/article/view/10254</self-uri><abstract><sec><title>Введение</title><p>Введение. Сахарный диабет (СД) остается одной из наиболее распространенных хронических патологий: по данным на октябрь 2024 г., в стране зарегистрировано более 5 млн пациентов, преимущественно с СД 2-го типа, при этом значительная часть случаев выявляется лишь при активном скрининге. Наряду с традиционными органами-мишенями, легкие рассматриваются как потенциально уязвимая структура, однако их поражение при диабете изучено недостаточно. Современные данные указывают на более высокую распространенность СД среди пациентов с интерстициальными заболеваниями легких (ИЗЛ), включая идиопатический легочный фиброз, однако влияние диабета как самостоятельной патологии на течение ИЗЛ остается недостаточно изученным.</p></sec><sec><title>Цель</title><p>Цель. Определить особенности клинической картины и функциональных нарушений у пациентов с хроническими интерстициальными заболеваниями легких различной этиологии, осложненными наличием сахарного диабета.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведено поперечное когортное ретро-проспективное исследование с участием 126 пациентов. Основную группу (1-я группа) составили 70 пациентов ИЗЛ в сочетании с СД, группу сравнения (2-я группа) – 56 пациентов с ИЗЛ без диабета. Критерием включения являлось наличие СД как самостоятельного заболевания. Всем пациентам выполнялись сбор анамнеза, анализ рентген-архива, тест 6-минутной ходьбы, бодиплетизмография и оценка диффузионной способности легких. Результаты. Группы были сопоставимы по полу, возрасту и нозологической структуре. У пациентов с сочетанной патологией отмечались более длительное течение заболевания, более высокая частота одышки и слабости, выраженное снижение толерантности к физической нагрузке, более значимые нарушения ОФВ1 и диффузионной способности легких, а также потребность в более интенсивной терапии.</p></sec><sec><title>Выводы</title><p>Выводы. Сахарный диабет оказывает неблагоприятное влияние на клинико-функциональные показатели у пациентов с хроническими ИЗЛ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Diabetes mellitus (DM) remains one of the most prevalent chronic diseases: as of October 2024, more than 5 million patients are registered in the country, predominantly with type 2 DM, while a substantial proportion of cases are identified only through active screening. In addition to traditional target organs, the lungs are considered a potentially vulnerable structure; however, pulmonary involvement in diabetes remains insufficiently studied. Current evidence indicates a higher prevalence of DM among patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, yet the impact of diabetes as an independent condition on the course of ILD remains unclear.</p></sec><sec><title>Aim</title><p>Aim. To determine the clinical and functional characteristics of patients with chronic interstitial lung diseases of various etiologies complicated by diabetes mellitus.</p></sec><sec><title>Materials and мethods</title><p>Materials and мethods. A cross-sectional retrospective–prospective cohort study including 126 patients was conducted. The main group (group 1) consisted of 70 patients with ILD and concomitant DM, while the comparison group (group 2) included 56 patients with ILD without diabetes. Inclusion criteria required the presence of DM as an independent disease entity. All patients underwent medical history assessment, radiographic archive analysis, a 6-minute walk test, body plethysmography, and evaluation of diffusing capacity of the lungs.</p></sec><sec><title>Results</title><p>Results. The groups were comparable in terms of sex, age, and nosological structure. Patients with combined pathology demonstrated longer disease duration, a higher prevalence of dyspnea and weakness, reduced exercise tolerance, more pronounced impairment in FEV₁ and diffusing capacity, and a greater need for intensive therapy.</p></sec><sec><title>Conclusions</title><p>Conclusions. Diabetes mellitus has an adverse impact on clinical and functional parameters in patients with chronic ILDs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>коморбидность</kwd><kwd>толерантность к физической нагрузке</kwd><kwd>функция внешнего дыхания</kwd><kwd>диффузионная способность легких</kwd><kwd>идиопатический легочный фиброз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>comorbidity</kwd><kwd>exercise tolerance</kwd><kwd>pulmonary function</kwd><kwd>diffusing capacity of the lungs</kwd><kwd>idiopathic pulmonary fibrosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST.</mixed-citation><mixed-citation xml:lang="en">Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M et al. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69. https://doi.org/10.1164/rccm.202005-2032ST.</mixed-citation><mixed-citation xml:lang="en">Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M et al. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69. https://doi.org/10.1164/rccm.202005-2032ST.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, Raghu G. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023;61(4):2200957. https://doi.org/10.1183/13993003.00957-2022.</mixed-citation><mixed-citation xml:lang="en">Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, Raghu G. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023;61(4):2200957. https://doi.org/10.1183/13993003.00957-2022.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLоS ONE. 2016;11(3):e0151425. https://doi.org/10.1371/journal.pone.0151425.</mixed-citation><mixed-citation xml:lang="en">Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLоS ONE. 2016;11(3):e0151425. https://doi.org/10.1371/journal.pone.0151425.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hilberg O, Bendstrup E, Løkke A, Ibsen R, Fløe A, Hyldgaard C. Co-morbidity and mortality among patients with interstitial lung diseases: a populationbased study. Respirology. 2018;23(6):606–612. https://doi.org/10.1111/resp.13234.</mixed-citation><mixed-citation xml:lang="en">Hilberg O, Bendstrup E, Løkke A, Ibsen R, Fløe A, Hyldgaard C. Co-morbidity and mortality among patients with interstitial lung diseases: a populationbased study. Respirology. 2018;23(6):606–612. https://doi.org/10.1111/resp.13234.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108(4):647–653. https://doi.org/10.1016/j.rmed.2014.01.008.</mixed-citation><mixed-citation xml:lang="en">Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108(4):647–653. https://doi.org/10.1016/j.rmed.2014.01.008.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Magliano DJ, Boyko EJ. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/35914061.</mixed-citation><mixed-citation xml:lang="en">Magliano DJ, Boyko EJ. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/35914061.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104–112. (In Russ.) https://doi.org/10.14341/DM2004116-17.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis. 1976;113(1):37–41. https://doi.org/10.1164/arrd.1976.113.1.37.</mixed-citation><mixed-citation xml:lang="en">Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis. 1976;113(1):37–41. https://doi.org/10.1164/arrd.1976.113.1.37.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bai L, Zhang L, Pan T, Wang W, Wang D, Turner C et al. Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review. Respir Res. 2021;22(1):175. https://doi.org/10.1186/s12931-021-01760-6.</mixed-citation><mixed-citation xml:lang="en">Bai L, Zhang L, Pan T, Wang W, Wang D, Turner C et al. Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review. Respir Res. 2021;22(1):175. https://doi.org/10.1186/s12931-021-01760-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kang Q, Ren J, Cong J, Yu W. Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study. BMC Pulm Med. 2024;24(1):142. https://doi.org/10.1186/s12890-024-02961-7.</mixed-citation><mixed-citation xml:lang="en">Kang Q, Ren J, Cong J, Yu W. Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study. BMC Pulm Med. 2024;24(1):142. https://doi.org/10.1186/s12890-024-02961-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mari YM, Fraix MP, Agrawal DK. Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face. Arch Intern Med Res. 2024;7(1):53–70. https://doi.org/10.26502/aimr.0165.</mixed-citation><mixed-citation xml:lang="en">Mari YM, Fraix MP, Agrawal DK. Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face. Arch Intern Med Res. 2024;7(1):53–70. https://doi.org/10.26502/aimr.0165.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol. 2012;11:132. https://doi.org/10.1186/1475-2840-11-132.</mixed-citation><mixed-citation xml:lang="en">Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol. 2012;11:132. https://doi.org/10.1186/1475-2840-11-132.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kolahian S, Leiss V, Nürberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019;20(3):303–319. https://doi.org/10.1007/s11154019-09516-w.</mixed-citation><mixed-citation xml:lang="en">Kolahian S, Leiss V, Nürberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019;20(3):303–319. https://doi.org/10.1007/s11154019-09516-w.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rajasurya V, Gunasekaran K, Surani S. Interstitial lung disease and diabetes. World J Diabetes. 2020;11(8):351–357. https://doi.org/10.4239/wjd.v11.i8.351.</mixed-citation><mixed-citation xml:lang="en">Rajasurya V, Gunasekaran K, Surani S. Interstitial lung disease and diabetes. World J Diabetes. 2020;11(8):351–357. https://doi.org/10.4239/wjd.v11.i8.351.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Rasmussen F, Bendstrup E. Clusters of comorbidities in idiopathic pulmonary fibrosis. Respir Med. 2021;187:106571. https://doi.org/10.1016/j.rmed.2021.106490.</mixed-citation><mixed-citation xml:lang="en">Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Rasmussen F, Bendstrup E. Clusters of comorbidities in idiopathic pulmonary fibrosis. Respir Med. 2021;187:106571. https://doi.org/10.1016/j.rmed.2021.106490.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Teague TT, Payne SR, Kelly BT, Dempsey TM, McCoy RG, Sangaralingham LR, Limper AH. Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Chest. 2022;161(1):101–111. https://doi.org/10.1186/s12931-022-02001-0.</mixed-citation><mixed-citation xml:lang="en">Teague TT, Payne SR, Kelly BT, Dempsey TM, McCoy RG, Sangaralingham LR, Limper AH. Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Chest. 2022;161(1):101–111. https://doi.org/10.1186/s12931-022-02001-0.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, Selman M. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med. 2010;104(2):305–309. https://doi.org/10.1016/j.rmed.2009.08.013.</mixed-citation><mixed-citation xml:lang="en">García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, Selman M. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med. 2010;104(2):305–309. https://doi.org/10.1016/j.rmed.2009.08.013.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Oldham JM, Kumar D, Lee C, Patel SB, Takahashi-Manns S, Demchuk C et al. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015;148(3):692–700. https://doi.org/10.1378/chest.14-2714.</mixed-citation><mixed-citation xml:lang="en">Oldham JM, Kumar D, Lee C, Patel SB, Takahashi-Manns S, Demchuk C et al. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015;148(3):692–700. https://doi.org/10.1378/chest.14-2714.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Урясьев ОМ, Твердова ЛВ, Приступа МА. Взаимосвязь заболеваний легких и сахарного диабета. Наука молодых (Eruditio Juvenium). 2024;12(3):468–477. https://doi.org/10.23888/HMJ2024123468-477.</mixed-citation><mixed-citation xml:lang="en">Uryasyev OM, Tverdova LV, Pristupa MA. Relationship between lung diseases and diabetes mellitus. Science of the Young (Eruditio Juvenium). 2024;12(3):468–477. (In Russ.) https://doi.org/10.23888/HMJ2024123468-477.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bates M, Marais BJ, Zumla A. Tuberculosis comorbidity with communicable and noncommunicable diseases. Cold Spring Harb Perspect Med. 2015;5(11):a017889. https://doi.org/10.1101/cshperspect.a017889.</mixed-citation><mixed-citation xml:lang="en">Bates M, Marais BJ, Zumla A. Tuberculosis comorbidity with communicable and noncommunicable diseases. Cold Spring Harb Perspect Med. 2015;5(11):a017889. https://doi.org/10.1101/cshperspect.a017889.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis. 2013;13(5):436–448. https://doi.org/10.1016/S1473-3099(13)70015-X.</mixed-citation><mixed-citation xml:lang="en">Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis. 2013;13(5):436–448. https://doi.org/10.1016/S1473-3099(13)70015-X.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sarker M, Barua M, Guerra F, Saha A, Aftab A, Latif AH et al. Double trouble: prevalence and factors associated with tuberculosis and diabetes comorbidity in Bangladesh. PLoS ONE. 2016;11(10):e0165396. https://doi.org/10.1371/journal.pone.0165396.</mixed-citation><mixed-citation xml:lang="en">Sarker M, Barua M, Guerra F, Saha A, Aftab A, Latif AH et al. Double trouble: prevalence and factors associated with tuberculosis and diabetes comorbidity in Bangladesh. PLoS ONE. 2016;11(10):e0165396. https://doi.org/10.1371/journal.pone.0165396.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Байсултанова РЭ, Рачина СА, Котидис ИМ, Купрюшина ОА, Альхаласех С. Практика лечения внебольничной пневмонии у взрослых пациентов с сахарным диабетом 2-го типа в многопрофильном стационаре. Пульмонология. 2022;32(4):568–575. https://doi.org/10.18093/0869-0189-2022-32-4-568-575.</mixed-citation><mixed-citation xml:lang="en">Baysultanova RE, Rachina SA, Kotidis IM, Kupriushina OA, Alhalaseh S. Management of community-acquired pneumonia in adults with type 2 diabetes mellitus in a multidisciplinary hospital. Pulmonologiya. 2022;32(4):568–575. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-4-568-575.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Степанян ИЭ. Особенности заболеваний легких при сахарном диабете. Практическая пульмонология. 2009;(4):8–12. Режим доступа: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_4_2009_02.pdf.</mixed-citation><mixed-citation xml:lang="en">Stepanyan IE. Features of lung diseases in diabetes mellitus. Prakticheskaya Pulʹmonologiya. 2009;(4):8–12. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_4_2009_02.pdf.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
